Effectiveness and safety of high-dose cyclophosphamide as salvage therapy for high-risk multiple myeloma and plasma cell leukemia refractory to new biological agents

Am J Hematol. 2011 Aug;86(8):699-701. doi: 10.1002/ajh.22054. Epub 2011 May 31.
No abstract available

MeSH terms

  • Adult
  • Aged
  • Antineoplastic Agents / therapeutic use
  • Antineoplastic Agents, Alkylating / administration & dosage
  • Antineoplastic Agents, Alkylating / adverse effects
  • Antineoplastic Agents, Alkylating / therapeutic use*
  • Boronic Acids / therapeutic use
  • Bortezomib
  • Cyclophosphamide / administration & dosage
  • Cyclophosphamide / adverse effects
  • Cyclophosphamide / therapeutic use*
  • Drug Resistance, Neoplasm*
  • Hospitals, University
  • Humans
  • Immunologic Factors / therapeutic use
  • Leukemia, Plasma Cell / drug therapy*
  • Middle Aged
  • Multiple Myeloma / drug therapy*
  • Protease Inhibitors / therapeutic use
  • Pyrazines / therapeutic use
  • Retrospective Studies
  • Salvage Therapy* / adverse effects
  • Severity of Illness Index
  • Survival Analysis

Substances

  • Antineoplastic Agents
  • Antineoplastic Agents, Alkylating
  • Boronic Acids
  • Immunologic Factors
  • Protease Inhibitors
  • Pyrazines
  • Bortezomib
  • Cyclophosphamide